ASAM Launches Corporate Roundtable

The ASAM Corporate Roundtable (CRT) was created this year to allow leaders in the addiction community to support key ASAM initiatives. Support for the CRT is growing, and the first program to benefit is the Patient Advocacy Task Force.

The Corporate Roundtable is a membership entity with different giving levels and annual membership, said Penny Mills, MBA, ASAM Executive Vice President and CEO. The ASAM Board of Directors decides each year how to use the funds raised through the CRT.

The following companies have joined the CRT so far and their levels of support are: Visionary Level, Reckitt Benckiser; Leader Level, Millennium Laboratories; Advocate Level, Alkermes; Friend Level, BHG, Cigna, Orexo and Pfizer.

Corporate Roundtable membership provides an opportunity to share vision, intellect, and financial resources with the addiction medicine community. Its resources will be used to support Board-designated initiatives that will help improve the quality, access, and delivery of addiction care, and the training and resources for addiction medicine specialists.

To learn more about the CRT, go to the “Get Involved” tab on the ASAM website.

The Patient Advocacy Task Force was developed to gather data and educate policy makers about the importance of effective patient access to medications for treatment of opioid addiction. A Stakeholder Summit is scheduled for June 20 in Washington, D.C., to release the results of the Task Force research and its analysis results, and to solicit feedback from stakeholders.

“The Corporate Roundtable is an opportunity to partner with leading corporate supporters in the field and identify mutual areas of interest in which we cooperate,” said ASAM President Stuart Gitlow, MD, MPH, MBA, FAPA. “We look forward to the continued growth of the Roundtable membership in the future to benefit the addiction community.”